News
The phase 1b PRECISE-AD trial is currently investigating PMN310 in patients with mild cognitive impairment due to AD and in those with mild AD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback